Cargando…

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review

Historically, metastatic melanoma was considered a highly lethal disease. However, recent advances in drug development have allowed a significative improvement in prognosis. In particular, BRAF/MEK inhibitors and anti-PD1 antibodies have completely revolutionized the management of this disease. None...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garutti, Mattia, Targato, Giada, Buriolla, Silvia, Palmero, Lorenza, Minisini, Alessandro Marco, Puglisi, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227121/ https://www.ncbi.nlm.nih.gov/pubmed/34071228 http://dx.doi.org/10.3390/cells10061334

Ejemplares similares

“To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers
por: Garutti, Mattia, et al.
Publicado: (2020)

CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature
por: Targato, Giada, et al.
Publicado: (2022)

Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
por: Garutti, Mattia, et al.
Publicado: (2021)

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer
por: Roncato, Rossana, et al.
Publicado: (2022)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study
por: Basile, Debora, et al.
Publicado: (2021)

Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
por: Lelliott, Emily J., et al.
Publicado: (2022)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

1741P Triage procedures for COVID-19 in an Italian cancer centre
por: Targato, G., et al.
Publicado: (2020)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer
por: Gerratana, Lorenzo, et al.
Publicado: (2020)

Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?
por: Bortot, Lucia, et al.
Publicado: (2022)

Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
por: AbuHammad, Shatha, et al.
Publicado: (2019)

Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
por: Palleschi, Michela, et al.
Publicado: (2020)

Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives
por: Dall’Acqua, Alessandra, et al.
Publicado: (2021)

Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
por: Ohara, Masahiro, et al.
Publicado: (2021)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
por: Arsenijevic, Tatjana, et al.
Publicado: (2023)

CDK4/6 inhibitor resistance: A bibliometric analysis
por: Pang, Jiayuecheng, et al.
Publicado: (2022)

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
por: Sottotetti, Federico, et al.
Publicado: (2022)

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma
por: MAHGOUB, T., et al.
Publicado: (2015)

Sex and Gender Disparities in Melanoma
por: Bellenghi, Maria, et al.
Publicado: (2020)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
por: Di Lauro, V., et al.
Publicado: (2022)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience
por: Barba, Maddalena, et al.
Publicado: (2021)

Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association
por: Marcianò, Antonia, et al.
Publicado: (2020)

Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma
por: Puglisi, Rossella, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i37gsg2csrk8fmurtufavosh9d